Clinical trials: Acute Respiratory Distress Syndrome
Respiratory Distress Syndrome in Premature Infant
A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact
The purpose of this two-part Phase 2 study is to assess the safety, tolerability and efficacy of aerosolized SF-RI 1 (AeroFact) when delivered via nCPAP at two different doses.
- Trial name
- NCT03969992
- Testing
- AeroFact, nCPAP
- Where
- 41 sites in United States, Canada
- Volunteers
- 261 people
- Sponsor
- Aerogen Pharma Limited
Inadequate; Pulmonary Ventilation, Newborn, Infant, Very Low Birth Weight
Nasal Noninvasive NAVA in the Very Low Birth Weight Infant
The purpose of this study is to determine if a new type of mechanical ventilation, or breathing machine (called neurally adjusted ventilatory assist or NAVA), will provide additional support to infants who were born prematurely.
- Trial name
- NCT01785563
- Testing
- Nasal NIV-NAVA
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Tarah T Colaizy
Sepsis, Acute Lung Injury
Statins for Acutely Injured Lungs From Sepsis
Objective: assess the efficacy and safety of oral rosuvastatin in patients with sepsis-induced Acute Lung Injury (ALI). Hypothesis: Rosuvastatin therapy will improve mortality in patients with sepsis-induced ALI.
- Trial name
- SAILS (NCT00979121)
- Testing
- Rosuvastatin
- Where
- 40 sites in United States
- Volunteers
- 745 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Respiratory Distress Syndrome, Influenza
STIP: Statin Trial for Influenza Patients
To assess the efficacy and safety of oral rosuvastatin in patients with suspected or confirmed influenza who require intensive care unit (ICU) admission due to respiratory distress.
- Conditions
- Acute Respiratory Distress Syndrome, Influenza, H1N1 Influenza
- Trial name
- STIP (NCT00970606)
- Testing
- Rosuvastatin (crestor)
- Where
- 21 sites in United States
- Volunteers
- 7 people
- Sponsor
- Gordon Bernard
Acute Lung Injury, Acute Respiratory Distress Syndrome
The Role of Circulating Soluble CD74 in Acute Lung Injury
Efforts to identify circulating factors that predict severity of acute lung injury/acute respiratory distress syndrome（ALI/ARDS） patients is unrevealing.
- Trial name
- NCT02201446
- Where
- China
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
COVID-19, ARDS
Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS
To evaluate the safety and efficacy of intravenous administration of bone marrow derived extracellular vesicles, ExoFlo, versus placebo as treatment for moderate-to-severe Acute Respiratory Distress Syndrome (ARDS) in patients…
- Trial name
- EXIT-COVID19 (NCT04493242)
- Testing
- ExoFlo, Intravenous normal saline
- Where
- 6 sites in United States
- Volunteers
- 102 people
- Sponsor
- Direct Biologics, LLC
Respiratory Distress Syndrome, Newborn
A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age
This study is to evaluate the safety and efficacy of lucinactant for inhalation in conjunction with nCPAP, in comparison to nCPAP alone, in preterm neonates with RDS, as assessed by the incidence of and time to respiratory…
- Trial name
- NCT04264156
- Testing
- Lucinactant for Inhalation, nCPAP Only
- Where
- 3 sites in Poland
- Volunteers
- 12 people
- Sponsor
- Windtree Therapeutics
Corona Virus Infection, Acute Respiratory Distress Syndrome
Losartan for Patients With COVID-19 Not Requiring Hospitalization
This is a multi-center, double-blinded study of COVID-19 infected patients randomized 1:1 to daily losartan or placebo for 10 days or treatment failure (hospital admission).
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
- Trial name
- NCT04311177
- Testing
- Losartan
- Where
- 4 sites in United States
- Volunteers
- 117 people
- Sponsor
- University of Minnesota
Respiratory Distress Syndrome, Newborn
Delivery Room Management Trial of Premature Infants at High Risk of Respiratory Distress Syndrome
The best mode of delivery room stabilization for premature infants at high risk for respiratory distress syndrome is unknown. The protocol evaluates the impact of three distinct methods of post-delivery stabilization and…
- Trial name
- NCT00244101
- Testing
- PS Group, NCPAP Group, ISX Group
- Where
- United States
- Volunteers
- 648 people
- Sponsor
- Vermont Oxford Network
COVID, Corona Virus Infection
Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms
The study is a prospective, randomized, controlled investigation designed for comparison of two groups for the reduction of respiratory distress in a CoViD-19 population, using gammaCore Sapphire (nVNS) plus standard of care…
- Conditions
- COVID, Corona Virus Infection, Respiratory Failure, Respiratory Distress Syndrome, Adult
- Trial name
- SAVIORII (NCT04382391)
- Testing
- gammaCore® Sapphire (non-invasive vagus nerve stimulator), Standard of care therapies
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Mechanical Ventilation, Single-lung Ventilation
Assessment of the Capability of PulmoVista 500 to Continuously Monitor Changes of Ventilation Over Time
The results of this study will help to define the capability and reliability of PulmoVista 500 to detect changes in both global and regional ventilation.
- Conditions
- Mechanical Ventilation, Single-lung Ventilation, ARDS, ALI - Acute Lung Injury
- Trial name
- NCT03076983
- Testing
- Lung Monitoring with EIT device (PulmoVista 500)
- Where
- 3 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Drägerwerk AG & Co. KGaA
Prone Positioning, High Flow Nasal Cannula
Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS
Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and had subsequently spread worldwide. Twenty-nine percent of COVID-19 patients may develop ARDS.
- Conditions
- Prone Positioning, High Flow Nasal Cannula, Acute Respiratory Distress Syndrome, Corona Virus Infection
- Trial name
- NCT04325906
- Testing
- high flow nasal cannula (HFNC), Prone positioning (PP)
- Where
- United States
- Volunteers
- 224 people
- Sponsor
- Rush University Medical Center
Acute Respiratory Distress Syndrome
Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)
The purpose of this study was to evaluate the efficacy and safety of poractant alfa (Curosurf®), administered by endotracheal (ET) instillation in hospitalized adult patients diagnosed with SARS-COV-19 acute respiratory distress…
- Trial name
- NCT04502433
- Testing
- CUROSURF® (poractant alfa)
- Where
- 6 sites in United States, Italy and 1 more
- Volunteers
- 22 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Respiratory Distress Syndrome, Bronchopulmonary Dysplasia
Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants
The primary aim of this study is to quantify and compare changes in lung volumes (as measured by functional residual capacity) in premature infants stable on continuous positive airway pressure (CPAP), and then randomized to two…
- Trial name
- NCT02249143
- Testing
- CPAP and room air
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Oregon Health and Science University
Respiratory Distress Syndrome, Adult
Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)
This was a Phase 2a, randomized, double-blind, placebo-controlled, multi-center trial to assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) infusion in…
- Trial name
- START (NCT02097641)
- Testing
- Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells, Plasma-Lyte A
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Michael A. Matthay
2019 Novel Coronavirus Infection, COVID-19 Virus Infection
Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19
This trial will study the use of USB002 given as an intravenous infusion in patients with respiratory distress due to infection with COVID-19.
- Conditions
- 2019 Novel Coronavirus Infection, COVID-19 Virus Infection, SARS Coronavirus 2 Infection, SARS-CoV-2 Infection
- Trial name
- NCT04778059
- Testing
- USB002
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- US Biotest, Inc.
Transient Tachypnea of the Newborn
Fluid Management in Transient Tachypnea of the Newborn
Transient tachypnea of the newborn (TTN) is a diagnosis given to infants born between 34 and 42 weeks gestation who develop difficulty breathing during the first days of life when no specific cause of the breathing difficulty can…
- Trial name
- NCT01225029
- Testing
- Amount of total fluids
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Coronavirus Infections, Pneumonia, Viral
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19
The scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (SARS-Cov-2) originated in China in December 2019.
- Conditions
- Coronavirus Infections, Pneumonia, Viral, Acute Respiratory Distress Syndrome
- Trial name
- NoCovid (NCT04305457)
- Testing
- Nitric Oxide
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- Massachusetts General Hospital
Acute Lung Injury, Acute Respiratory Distress Syndrome
Airway Pressure Release Ventilation in Acute Lung Injury
The purpose of this study is to compare airway pressure release ventilation (APRV) to conventional mechanical ventilation (MV) in patients with acute lung injury (ALI) to determine if APRV can reduce agitation, delirium, and…
- Conditions
- Acute Lung Injury, Acute Respiratory Distress Syndrome, Mechanical Ventilation
- Trial name
- NCT00750204
- Testing
- APRV, Conventional MV
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Johns Hopkins University
Acute Respiratory Distress Syndrome, Critical Illness
A Study Promoting Critical Illness Recovery in the Elderly
This proposal will test the hypothesis that EARLY application of a novel early rehabilitation therapy in critically ill patients will improve functional outcomes, and change the functional trajectory of this population.
- Conditions
- Acute Respiratory Distress Syndrome, Critical Illness, Critical Care
- Trial name
- ASPIRE (NCT02963558)
- Testing
- cycle ergometry
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wake Forest University Health Sciences